Literature DB >> 17985679

Screening HIV in pregnancy: a survey of prenatal care patients.

Veronique Dorval1, Kerri Ritchie, Andrée Gruslin.   

Abstract

BACKGROUND: Women in Canada, as in the rest of the world, represent an increasing proportion of new HIV positive cases. In 2002, women accounted for 25% of all positive HIV tests reported in Canada; with the majority being in their childbearing years (15 to 39 years), perinatal transmission of HIV in Canada is cause for concern. Following the development of interventions that can effectively reduce vertical transmission rate, prenatal screening of HIV has become the first and most pivotal step in the prevention of mother-to-child HIV transmission. The purpose of this study was to assess how women's knowledge and attitudes regarding HIV and HIV screening in pregnancy influence screening rates.
METHOD: A prospective anonymous survey of 231 women attending antenatal care clinics at a teaching university hospital or in a community clinic was conducted.
RESULTS: In general, pregnant women supported universal HIV screening in the prenatal period. Women who previously had been tested for HIV and who did not perceive that they were at risk for contracting HIV were more likely to decline HIV testing in their current pregnancy. Overall knowledge regarding HIV and its transmission is less than optimal, particularly among those women who declined HIV testing.
CONCLUSION: Knowledge gaps exist between women accepting and declining prenatal HIV screening, particularly relating to benefits of screening. These results suggest that efforts have to continue to be put into educating the public but also, importantly, into changing current attitudes.

Entities:  

Mesh:

Year:  2007        PMID: 17985679      PMCID: PMC6976025     

Source DB:  PubMed          Journal:  Can J Public Health        ISSN: 0008-4263


  13 in total

1.  Aiming for zero: preventing mother-to-child transmission of HIV.

Authors:  Kathleen Steel O'Connor; Susan E MacDonald
Journal:  CMAJ       Date:  2002-04-02       Impact factor: 8.262

2.  Failure to prevent perinatal HIV infection.

Authors:  Ari Bitnun; Susan M King; Cheryl Arneson; Stanley E Read
Journal:  CMAJ       Date:  2002-04-02       Impact factor: 8.262

Review 3.  Opt in or opt out: what is optimal for prenatal screening for HIV infection?

Authors:  Sharon Walmsley
Journal:  CMAJ       Date:  2003-03-18       Impact factor: 8.262

4.  Potential factors that may affect acceptance of routine prenatal HIV testing.

Authors:  Fu-Lin Wang; Bryce Larke; Stephan Gabos; Anita Hanrahan; Donald Schopflocher
Journal:  Can J Public Health       Date:  2005 Jan-Feb

5.  Acceptance of HIV testing during prenatal care. Perinatal Guidelines Evaluation Project.

Authors:  M I Fernández; T E Wilson; K A Ethier; E B Walter; C L Gay; J Moore
Journal:  Public Health Rep       Date:  2000 Sep-Oct       Impact factor: 2.792

6.  Universal prenatal HIV screening: patient attitudes and perceptions.

Authors:  Kristin A Kelly; Chase H Harrison
Journal:  Women Health       Date:  2004

7.  Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa.

Authors:  E Marseille; J G Kahn; F Mmiro; L Guay; P Musoke; M G Fowler; J B Jackson
Journal:  Lancet       Date:  1999-09-04       Impact factor: 79.321

8.  Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml.

Authors:  J P Ioannidis; E J Abrams; A Ammann; M Bulterys; J J Goedert; L Gray; B T Korber; M J Mayaux; L M Mofenson; M L Newell; D E Shapiro; J P Teglas; C M Wilfert
Journal:  J Infect Dis       Date:  2001-01-12       Impact factor: 5.226

9.  With HIV prevalence among women increasing, more provinces encourage prenatal testing.

Authors:  A Silversides
Journal:  CMAJ       Date:  1998-06-02       Impact factor: 8.262

10.  Epidemiologic modeling to evaluate prevention of mother-infant HIV transmission in Ontario.

Authors:  Robert S Remis; Susan M King; Lee Vernich; Carol Major; Elaine Whittingham
Journal:  J Acquir Immune Defic Syndr       Date:  2003-10-01       Impact factor: 3.731

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.